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Heterotopic Heart Transplantation in the Rat Receiving 
FK-506 Alone or With CycIosporine 
N. Murase, S. Todo, P-H. Lee, H-S. Lai, F. Chapman, M.A. Nalesnik, L. Makowka, and T.E. Starzl 
I N THE FIRST IN VIVO demonstration of immunosuppression by FK-506 (FK), 
Ochiai et all used inbred rats. The potency 
and safety of the agent was confirmed in rats 
by Lee et al2 who provided further informa-
tion about dose-effect relationships and about 
dose timing. In the present study, longer fol-
low-up will be provided for Lee's experiments, 
evidence will be presented that FK and cyclo-
sporine (eyA) are synergistic, and prelimi-
nary experiments will be described that test 
the hypothesis that partial tolerance induction 
may be achieved with a brief course of prop-
erly timed FK administration. 
MATERIALS AND METHODS 
Animals 
Inbred male rats were used in all experiments. Lewis 
rats (RTl') weighing 200 to 250 g were always used as 
recipients. ACI rats (RTla) weighing 150 to 200 g were 
used as heart donors except for a few experiments 
studying specific tolerance induction in which Brown 
Norway (BN) rats (RTln) were used as donors. Lewis 
(LEW) rats and BN rats were purchased from Harlan 
Sprague Dawley (Indianapolis). ACI rats were purchased 
from Simonsen Laboratories (Gilcoy, CAl. 
Operative Procedures 
Anesthesia was with 40 mg/kg phenobarbital intra-
peritoneally. Hearts usually were transplanted heterotop-
ically by anastomosing the donor aorta and pulmonary 
artery to the recipient aorta and infrarenal inferior vena 
cava.3 The transplanted hearts were palpated daily 
through the abdominal wall. Rejection was diagnosed by 
the cessation of heart beat and confirmed visually by 
laparotomy and histological examination. Recipient rats 
that died with living grafts were excluded from statistical 
analysis; these exclusions accounted for less than 5% of 
the experiments. All animals are accounted for individu-
ally in the tables. 
In the tolerance induction studies in which two heart 
transplants were performed serially, the second graft was 
inserted in the neck by a modification of Heron's method' 
whereby the aorta is anastomosed to the carotid artery 
and the pulmonary artery is anastomosed to the jugular 
vein. 
Drug Administration 
The Fujisawa Pharmaceutical Co, Ltd, Osaka, Japan, 
provided FK as a crystalline powder. It was dissolved in 
saline and was injected in the thigh once a day. 
Experimental Designs 
Dose-response studies. These experiments with 
shorter follow-up were reported previously by Lee et al.2 
Forty-two recipient rats were divided into seven groups of 
six to test the effectiveness of FK in doses from 0.02 to 
1.28 mg/kg/d. In all seven groups, treatment was for 2 
weeks (Table I), starting just after recovery from anes-
thesia. Graft survival times were compared by using 
Wilcoxon rank sum testing. 
Treatment timing studies. The most effective dose 
was judged from the dose-response studies to be 1.28 
mg/kg/d. With this daily dosage, six groups of animals 
were treated at various time intervals before transplanta-
tion (Table 2). Another four groups were treated at 
different times after transplantation (Table 3). From one 
to 4 doses were given (Tables 2 and 3). The experiments 
in Tables 2 and 3 were the same as reported by Lee et af 
but with a longer follow-up. 
Studies of possible tolerance induction. The most 
striking results in the treatment timing studies were with 
intramuscular doses of 1.28 mg/kg on days 4, 5, and 6 
after grafting (see Table 3). The grafts were not only 
rescued from rejection, but they survived for long times 
thereafter it not permanently. 
The possibility of donor-specific antigen nonrespon-
siveness was analyzed with the experiments in Table 3. 
The actual experiments were in group 22 in which ACI 
rats provided serial heart grafts 14 days apart and in 
group 23 in which the second graft was provided by a 
third party (BN) donor. The other groups were controls, 
with the meanings summarized in Table 4. 
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Table 1. Effect of Intramuscular FK Dose for 14 Days Starting the Day of Heterotopic Heart Transplantation 
Dose Median PValue v 
Group (mg}kg' n Graft Survival (d' Survival (d' Group 1 
1 0.00 7 6,6,6,6,7,7,7 6.0 
2 0.02 6 7,7,8,8,9,9 8.0 <.05 
3 0.04 6 9,10,10, 11,24,34 10.5 <.01 
4 0.08 6 12, 14,32,36,40,10- 32.0 <.01 
5 0.16 6 27,30,32,33,55,14- 32.0 <.01 
6 0.32 6 27,30,37,39,39,49 38.0 <.01 
7 0.64 6 33,34,36,42,43,84 39.0 <.01 
8 1.28 6 56,71,80,94,96,>200 87.0 <.01 
·Diad with a living graft. 
Table 2. Preoperative Treatment With One to Four Doses of 1.28 mg/kg Intramuscular FK 
Days Preoperative FK 





12 X X 
13 X X X 
14 X X X X 
-Died with a living graft. 
Intramuscular FK in combination with oral 
CyA. The experimental design using ACI·LEW heart 
transplants is summarized in Table 5. Minimally effective 
doses of intramuscular FK or oral CyA were combined. 
RESULTS 
Dose-Response Studies 
Untreated rats rejected their hearts in six 
days (Table 1). Graft survival was signifi-
cantly increased with doses as small as 0.02 
mg/kg, and major survival increases were 
demonstrated at all doses greater than 0.04 
mg/kg. The great range of dose effectiveness 
(to as high as 1.28 mg/kg) with little or no 
Graft Median 
n Survival (d' Survival (d' 
7 6,6,6,6,7,7,7 6.0 
3 7,8,9 8.0 
3 8,8,8 8.0 
3 6,6,6 6.0 
3 18,30,37 30.0 
3 33,35.48 35.0 
6 30,31.32,35,51,6* 32.0 
mortality was noteworthy, implying a favor-
able therapeutic index. Nalesnik et al5 are 
reporting elsewhere in this symposium that 
weight loss and other potential complications 
of FK are minor in rats. 
The most effective dose was 1.28 mg/kg. 
When this dose was given daily for 2 weeks, all 
hearts beat for at least 6 more weeks without 
therapy, and one is still going more than a half 
year later. 
Treatment Timing Studies 
Two or more intramuscular doses of 1.28 
mg/kg FK prolonged heart graft survival 
Table 3. Postoperative Treatment With Two or Three Doses of 1.28 mg/kg Intramuscular FK 
Days Preoperative FK Graft Median 
Group 0 2 3 4 5 6 n Survival (d' Survival (d' 
Nona 7 6,6,6.6.7,7,7 6.0 
15 X X 3 22.31,53 31.0 
16 X X X 3 23,35,36 35.0 
17 X X 3 30.49,53 49.0 
18 X X X 6 23. 51, 89, 93. 98, 89.0 
>145 
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Table 4. Fate of Double Heart Transplants With Three-Day Course of 1.28 mg/kgl d Intramuscular FK 
Strain 
Group Combinations 
1st HTx, ACI-lEW 
19 1st HTx, BN-lEW 
20 Delayed HTx, ACI-
LEW 
21 Delayed HTx, BN-lEW 
22 1st HTx, ACI-lEW 
Tome Sequence Over 14-Day Period 
1st HTx on 
Day 0 and 
Survival (dl 
Yes (6, 6, 6, 6, 7, 
7,7) 
Yes(11, 11, 11, 








Days 4, 5, and 6 Survival (dl . 
No No 
No No 
Yes Yes (9, 10, 10, 11) 
Yes Yes (27,34) 
Yes 
Meaning of Group 
Untreated control, 
same as group 1, 
Table 1 
Untreated control, with 
BN-LEW strain com-
bination 
Measures effect of 3 
days' treatment 7-
1 0 days before de-
layed grafting 
Measures effect of 3 
days' treatment 7-
10 days before de-
layed grafting with 
easier BN-LEW com-
bination 
Confirms group 18, Ta-
ble 3, and conditions 
recipient for 2nd 
graft 
2nd HTx, ACI-LEW Yes (25, 41,49, 56) Test of donor-specific 
23 1 st HTx, ACI-Lew Yes (48,60) 
2nd HTx, BN-lEW 
Test groups are groups 22 and 23; all others are controls. 
Abbreviation: HTx, heart transplant. 
Yes 
Yes (14, 15) 
tolerance without 
further FR treatment, 
ACI donor P< .01 v 
group 20 
Same result with 1 st 
Htx as in group 22 
Minimal survival advan-
tage for 2nd graft 
using BN donor 
Table 5. Effect of Intramuscular FK Combined with Oral CyA for 2 Weeks Starting After 
Recovery From Anesthesia 
Median 
Group Treatment n Graft Survival (dl Survival (dl PValue 
1 Untreated control 7 6,6,6,6,7,7,7 6.0 
2 FK, 0.02 mg/kg/d 6 7,7,8,8,9,9 8.0 <.05 v 1 
3 FK, 0.04 mg/kg/d 6 ~ 10, 10, 11,24,34 10.5 <.01 v 1 
24 CyA, 2.5 mg/kg/d 6 7,9,9,11,15,19 10.0 <.01 v 1 
25 FK, 0.02 mg/kg/d, +CyA, 2.5 6 24,25,26,26,38,51 26.0 <.01 v 2,3, and 24 
mg/kg/d 
26 FK, 0.04 mg/kg/d, +CyA, 2.5 6 15,21,34,36,48,53 35.0 <.01 v 2,3, and 24 
mg/kg/d 
74 
remarkably (Table 3). In group 18, three 
injections beginning almost on the eve of 
anticipated rejection rescued all six of the 
grafts. Furthermore, the subsequent survival 
was 2'/2 to 20 weeks, and the longest surviving 
graft is still beating (Table 3). These observa-
tions prompted the experiments in the next 
section. 
Studies of Possible Partial 
Tolerance Induction 
After four ACI-to-LEW transplants, the 
striking effect of 1.28 mg/kg FK on days 4, 5, 
and 6 after grafting was confirmed (group 22, 
Table 4). Placement eight days later of 
another ACI heart without further therapy 
did not precipitate rejection of the first organ, 
and the second grafts survived for 25 to 56 
days. Rejection was the usual eventual cause 
of loss of both the first and second heart. 
When the second heart donor was of the BN 
strain (group 23, Table 4), most but not all of 
the foregoing potentiation of second-graft sur-
vival was lost. Control studies in groups 20 
and 21 explained why the third-party BN 
grafts of group 23 had a slight and unexpected 
survival prolongation. In these controls, treat-
ment of the LEW recipients for three days and 
ending eight days before transplantation of 
either ACI (group 20) or BN hearts (group 
21) resulted in a still-perceptible immunosup-
pressive effect compared with animals with no 
pretreatment at all (groups 1 and 19, Table 
4). 
FK Combined With CyA 
Small doses of FK alone or Cy A alone had 
caused barely detectable increases in graft 
survival. When used together, the drugs had a 
synergistic effect (Table 5). 
DISCUSSION 
The studies of dosage and timing have 
completed the profile already published in 
part by Lee et al.2 At the optimal dose tested 
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so far in a 2-week course of therapy, graft 
survival far outlasts discontinuance of treat-
ment, but survival of the now-treated graft is 
not usually permanent. The same applies if 
FK administration is delayed for several days 
after transplantation and then delivered in a 
burst that could theoretically lead to specific 
clone deletion as was speculated by Lee et al.2 
The possibility of creating selecting nonres-
ponsiveness was directly examined with drugs 
given delayed FK treatment and then chal-
lenged eight days later with a second cardiac 
graft from the same donor species while the 
original heart was still beating. The second 
heart graft had a great survival advantage in 
this conditioned environment, and the original 
heart transplant was not thereby harmed. The 
immunologic specificity of this effect was 
suggested by the fact that a survival advan-
tage for third-party (BN) hearts was very 
minor in comparison. 
The other new rat data in this ongoing 
study were concerned with the synergism 
between FK and CyA. Minimally therapeutic 
doses of these agents had a greatly amplified 
effect when the drugs were used together, 
which adds to the theme of multiple-drug 
therapy on which our attention has been 
focused in the event of clinical trials of FK. 
SUMMARY 
In rats, FK significantly prolonged hetero-
topic heart graft survival over a wide dose 
range when given for 2 weeks starting on the 
day of the operation. Brief courses of FK for 
one to four days preoperatively, and especially 
beginning four days postoperatively, allowed 
long subsequent survival of heart grafts in 
otherwise untreated recipients. The seeming 
acceptance of the grafts with postoperative 
FK treatment was largely but not exclusively 
donor specific when tested eight days after the 
last FK dose by second grafts from the same 
donor v third-party donor grafts. FK in mini-
mally therapeutic doses was synergistic with 
suboptimal doses of CyA. 
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